EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr ‐Mutant Lung Cancer Mouse Model

Takaaki Tanaka, Masato Fujitani, Masataka Taoka, Iwao Shimomura, Sachi Okawa, Shunta Mori, Tadahiro Kuribayashi, Jun Nishimura, Tomoka Nishimura, Ayako Morita, Naofumi Hara, Kiichiro Ninomiya und 11 weitere

Cancer Science · 2026

DOI: 10.1111/cas.70431 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Takaaki Tanaka und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, O…. Hauptthemen laut MEDLINE: Afatinib, Acrylamides, Drug Resistance, Neoplasm, Aniline Compounds. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Nippon Foundation, Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osimertinib is the standard first‐line treatment for advanced EGFR ‐mutant non‐small cell lung cancer. However, acquired resistance invariably develops, and identifying novel resistance pathways is clinically important as a substantial portion remains undefined. We used an immunocompetent syngeneic lung cancer mouse model harboring an Egfr exon 19 deletion (mDEL tumors) to establish acquired resistance. Osimertinib‐resistant tumors were generated in vivo using a drug‐holiday/re‐challenge protocol. The resistance mechanism was identified using Sanger sequencing, receptor tyrosine kinase arrays, and western blotting. Egfr V804F knock‐in cells were generated using CRISPR/Cas9, and their sensitivity to osimertinib and afatinib was assessed in vitro and in vivo. We established two distinct osimertinib‐resistant tumor lines in a syngeneic lung cancer mouse model (mDEL OsiR #1/#3). The analysis revealed an on‐target secondary Egfr V804F mutation (corresponding to human EGFR V802F) in both tumor lines. Importantly, Egfr V804F knock‐in cells demonstrated significant osimertinib resistance, with a 5.7–10.5‐fold increase in in vitro IC 50 (mean, 8.2‐fold), but remained highly sensitive to afatinib. Furthermore, afatinib effectively overcame osimertinib resistance in the V804F knock‐in cell‐derived mouse model. Consistently, afatinib treatment resulted in marked tumor shrinkage and suppression of EGFR signaling in the established mDEL OsiR #1/#3 in vivo. These findings establish secondary Egfr V804F/ EGFR V802F as an on‐target osimertinib resistance mechanism, providing a preclinical rationale for evaluating afatinib in biomarker‐selected patients harboring this alteration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AfatinibAcrylamidesDrug Resistance, NeoplasmAniline CompoundsLung NeoplasmsCarcinoma, Non-Small-Cell LungAnimalsPyrimidinesIndolesErbB ReceptorsMiceHumansMutationCell Line, TumorDisease Models, AnimalProtein Kinase Inhibitors

Stichwörter der Autor:innen

EGFR‐mutant NSCLCV802F (human EGFR)/V804F (murine Egfr)afatinibexon 19 deletionosimertinib resistance

Substanzen

AfatinibPyrimidinesAcrylamidesosimertinibIndolesAniline CompoundsErbB ReceptorsProtein Kinase InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
  • Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Department of Hematology, Oncology and Respiratory Medicine, Okayama University, Okayama, Japan.
  • Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.

ORCID-Profile: Eiki Ichihara, Shuta Tomida, Katsuyuki Hotta, Yosuke Togashi, Ryohei Katayama, Kadoaki Ohashi

Förderung

  • Japan Society for the Promotion of Science
  • Nippon Foundation
  • Boehringer Ingelheim
  • Japan Agency for Medical Research and Development

Zitieren

APA

Tanaka, T., Fujitani, M., Taoka, M., Shimomura, I., Okawa, S., Mori, S., Kuribayashi, T., Nishimura, J., Nishimura, T., Morita, A., Hara, N., Ninomiya, K., Makimoto, G., Higo, H., Rai, K., Ichihara, E., Tomida, S., Hotta, K., Togashi, Y., …, & Ohashi, K. (2026). Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr ‐Mutant Lung Cancer Mouse Model. Cancer Science. https://doi.org/10.1111/cas.70431

Vancouver

Tanaka T, Fujitani M, Taoka M, Shimomura I, Okawa S, Mori S, et al. Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr ‐Mutant Lung Cancer Mouse Model. Cancer Science. 2026. doi:10.1111/cas.70431

BibTeX
@article{Tanaka2026,
  author = {Tanaka, Takaaki and Fujitani, Masato and Taoka, Masataka and Shimomura, Iwao and Okawa, Sachi and Mori, Shunta and Kuribayashi, Tadahiro and Nishimura, Jun and Nishimura, Tomoka and Morita, Ayako and Hara, Naofumi and Ninomiya, Kiichiro and Makimoto, Go and Higo, Hisao and Rai, Kammei and Ichihara, Eiki and Tomida, Shuta and Hotta, Katsuyuki and Togashi, Yosuke and Maeda, Yoshinobu and Kiura, Katsuyuki and Katayama, Ryohei and Ohashi, Kadoaki},
  title = {Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr ‐Mutant Lung Cancer Mouse Model},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70431}
}
Kostenlos starten →